Centessa Pharmaceuticals plc (NASDAQ:CNTA) Short Interest Update

Centessa Pharmaceuticals plc (NASDAQ:CNTA) saw a significant decline in short interest in January. As of January 31st, there was short interest totalling 3,050,000 shares, a decline of 7.3% from the January 15th total of 3,290,000 shares. Currently, 3.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 678,600 shares, the short-interest ratio is currently 4.5 days.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 30,526 shares of the company’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $19.03, for a total transaction of $580,909.78. Following the sale, the insider now directly owns 54,322 shares in the company, valued at $1,033,747.66. This represents a 35.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CTO Tia L. Bush sold 11,000 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $16.86, for a total value of $185,460.00. Following the sale, the chief technology officer now owns 121,503 shares in the company, valued at approximately $2,048,540.58. This trade represents a 8.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 397,652 shares of company stock worth $6,871,582. Corporate insiders own 11.59% of the company’s stock.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC raised its holdings in shares of Centessa Pharmaceuticals by 279.2% in the fourth quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company’s stock valued at $82,218,000 after acquiring an additional 3,614,623 shares in the last quarter. Foresite Capital Management VI LLC purchased a new position in Centessa Pharmaceuticals during the 4th quarter valued at about $20,994,000. Franklin Resources Inc. raised its holdings in shares of Centessa Pharmaceuticals by 99.1% in the 3rd quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock valued at $38,360,000 after purchasing an additional 1,145,823 shares in the last quarter. Point72 Asset Management L.P. lifted its position in shares of Centessa Pharmaceuticals by 54.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company’s stock worth $43,423,000 after purchasing an additional 953,659 shares during the period. Finally, Adage Capital Partners GP L.L.C. boosted its stake in shares of Centessa Pharmaceuticals by 22.0% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company’s stock valued at $85,744,000 after purchasing an additional 924,027 shares in the last quarter. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on CNTA shares. TD Cowen started coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating on the stock. Guggenheim reissued a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Monday, February 10th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $25.83.

Centessa Pharmaceuticals Stock Down 4.7 %

Shares of NASDAQ CNTA opened at $16.26 on Wednesday. Centessa Pharmaceuticals has a 52-week low of $7.75 and a 52-week high of $19.09. The firm has a market capitalization of $2.14 billion, a price-to-earnings ratio of -10.63 and a beta of 1.53. The stock has a 50 day moving average price of $16.74 and a 200 day moving average price of $15.78. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.